Ask AI
Redefining HCC Treatment in the Immunotherapy Era

CE / CME

Redefining HCC Treatment in the Immunotherapy Era – Expert Insights, Multimodal Innovations, and Coordinated Care for Optimal Outcomes Across the Disease Continuum

ABIM MOC: maximum of 1.00 Medical Knowledge MOC point

Physicians: Maximum of 1.00 AMA PRA Category 1 Credit

Released: June 26, 2025

Expiration: December 25, 2025

Pretest

Progress
1 2
Course Completed
1.

How would you rate your confidence in collaborating with interventional radiologist and other members of the care team when appropriate to enhance patient-centered management of advanced HCC?

2.

Patient Case: 72-Yr-Old Woman With MASH Cirrhosis



  • 72-yr-old woman presents with MASH cirrhosis presents to the clinic

  • Patient’s MRI imaging revealed a liver lesion

    • LI-RADS 5 lesion measuring 6 x 5 cm

    • Possible secondary lesion (LIRADS 4/ Next slide)



  • ECOG PS: 1

  • Child-Pugh score: 5



Patient Case: Secondary Lesion on MRI Identified—LIRADS 4



  • Primary management is being considered

  • No portal vein involvement was identified


In a consultation with a patient to discuss treatment options, which of the following would you mention regarding the efficacy data for adding systemic immunotherapy to TACE based on the LEAP-012 and EMERALD-1 trials?

3.

In a patient receiving lenvatinib plus pembrolizumab and TACE, as in the LEAP-012 clinical trial, which of the following approaches would you recommend for management of grade 3 pancreatitis?